The Significance of Lactate and Lipid Peaks for Predicting Primary Neuroepithelial Tumor Grade with Proton MR Spectroscopy

Hisao Nakamura¹, Masatomo Doi², Takuya Suzuki¹, Yasuyuki Yoshida³, Masahiro Hoshikawa², Masashi Uchida³, Yuichiro Tanaka³, Masayuki Takagi², and Yasuo Nakajima¹

Purpose: ¹H-MRS is a non-invasive technique used to assess the metabolic activity of brain tumors. The technique is useful for the preoperative prediction of tumor grade, which is important for treatment planning and accurate prognosis. We used ¹H-MRS to study the lactate peak, which appears in various conditions, including hyperglycemia, ischemia, and hypoxia and lipid peak, which is associated with necrotic cells. The purpose of this study was to retrospectively examine the frequency and significance of lactate and lipid peaks in relation to brain tumor grade.

Materials and Methods: Fifty-five patients diagnosed with neuroepithelial tumors of Grades I (3 cases), II (11 cases), III (15 cases), and IV (26 cases) were enrolled. Biopsies were excluded. Single voxel (TE = 144 ms) point resolved ¹H-MRS spectroscopy sequences were retrospectively analyzed. An inverted doublet peak at 1.3 ppm was defined as lactate, a negative and positive peak was defined as combined lactate and lipid, and a clear upward peak was defined as lipid.

Results: Lactate peaks were detected in all grades of brain tumors and were least common in Grade II tumors (9.1%). The frequency of combined lactate-lipid peaks was 0% (Grades I and II), 8.3% (Grade III), and 44% (Grade IV). Grade IV tumors were significantly different to the other grades. There were three cases with a lipid peak. All were glioblastoma.

Conclusions: The presence of a lac peak may be useful to largely rule out the Grade II tumors, and allow the subsequent differentiation of Grade I tumors from Grade III or IV tumors by conventional imaging. The presence of a lipid peak may be associated with Grade IV tumors.

Keywords: lactate, lipid, magnetic resonance spectroscopy, brain tumor, glioma

Introduction

Lactate (Lac) production is considered to be an indicator of altered metabolism in brain tumors. Glucose metabolism is the sole mechanism by which the brain generates energy in the form of adenosine triphosphate (ATP). In the normal brain, glucose is oxidized completely to CO2 and H2O through the tricarboxylic acid (TCA) cycle and electron transport system to generate 36 mol ATP. However, if O2 is insufficient, the end product of glycolysis, pyruvate, cannot enter the TCA cycle and is converted to lactate generating 2 mol ATP. This lac producing pathway is referred to as “anaerobic glycolysis”, and results from a mismatch between glycolysis and oxygen supply.¹ Lactate accumulation in brain tumors is caused by increased glycolysis, and is associated with ischemic change in the poorly perfused tumor parenchyma,² or an increased incidence of necrotic tissue.³

Lipids (Lip) exist as a macromolecule in cell membranes and myelin sheaths in normal brain tissue. When brain tissue is damaged or disrupted as occurs during brain tumor growth, the lip macromolecules are transformed into mobile lip.⁴

¹H-MRS is a noninvasive approach for the evaluation of metabolic patterns in human brain tumors, and is useful for detecting lac and lip peaks. Lip can be detected by magnetic resonance spectroscopy (MRS) in high-grade tumors and is correlated with the amount of microscopic cellular necrosis.⁴ Several studies suggested that high-grade gliomas can be distinguished from low-grade tumors by higher lac peaks,⁵,⁶ although other researchers did not find a significant correlation.⁷,⁸
The purpose of this study was to retrospectively examine the correlation of lac and lip peak frequency with tumor grade, and evaluate the utility of lac and lip peak frequency for predicting tumor grade.

Materials and Methods

Study subjects
Fifty-five patients diagnosed with neuroepithelial tumors were enrolled from January 2007 to March 2013 at St. Marianna University of Hospital, Kawasaki, Japan. The patients included 34 men and 21 women, ranging in age from 26 to 73. Biopsies and recurrent cases were excluded. Histologic analyses was performed, according to the World Health Organization brain tumor classification revised in 2007. Three patients were diagnosed with Grade I tumors, 11 with Grade II tumors, 15 with Grade III tumors, and 26 with Grade IV tumors. Of the Grade I tumors, two were classified as pilocytic astrocytoma and one as dysplastic gangliocytoma. The Grade II tumors included four oligoastrocytoma, five diffuse astrocytoma, one ependymoma, and one pleomorphic xanthoastrocytoma. Of the Grade III tumors, 10 were anaplastic astrocytoma, four anaplastic oligoastrocytoma, and one anaplastic oligodendroglioma. The Grade IV tumors included 25 glioblastoma and one medulloblastoma.

Proton MRS
MR imaging was performed on all of the study patients with a 1.5T MR system (Achieva; Philips Healthcare, Best, The Netherlands). In all cases, single voxel 1H-MRS was performed with the same MR unit using a point resolved spectroscopy sequence (TR, 2000 ms; TE, 144 ms; average 128). Tumor regions of interest were identified on the basis of abnormal signal intensities seen on T2-weighted images (T2WI), fluid attenuated inversion recovery (FLAIR) and the enhancing portion of lesions seen on contrast-enhanced T1-weighted images (T1WI) after intravenous injection of 0.1 mmol/kg gadoterate meglumine (Dotarem; Guerbet, Paris, France). The voxel dimensions were 1.5 × 1.5 × 1.5 cm (total volume of 3.375 cm³). Experienced neuroradiologists (H. N., T. S.) carefully positioned the voxels to include the largest enhancing region and to avoid contamination by adjacent normal tissue, the skull base, any hemorrhagic or calcified regions, and the ventricular system. For unenhanced tumors, the volume of interest (VOI) was placed as carefully as possible to exclude the fluid portion.

The metabolites were assigned as choline (Cho) at 3.22 ppm, creatine (Cr) at 3.02 ppm, N-acetylaspartate (NAA) at 2.02 ppm, lipid at 0.9 to 1.3 ppm, and lactate at 1.33 ppm. A lactate peak was identified as an inverted doublet peak at TE = 144 ms. A negative peak in the left component, occurring with a decreased negative peak in the right component, and a positive peak at 1.3 ppm, was defined as combined lac and lip (lac/lip). Clear upward peaks at 1.3 and 0.9 were defined as lipid.

For the quantitative evaluation of lac peaks, excluding the lac/lip peak cases, the absolute height of the lac/normal control Cr ratio was used. The control Cr represented an area in the contralateral side, or a remote section of the lesion. A neuropathologist (M.D.) confirmed that the operative area corresponded with the VOI.

Ethical approval for this study (# 2491) was obtained from the Institutional Review Board of St. Marianna University.

Statistical analysis
The frequency of lac and lip peaks relative to tumor grade was evaluated by the Ryman method. The frequency of lac/lip combined peaks in Grade III and IV tumors was evaluated by the Fisher’s exact test. Kruskal-Wallis tests were used for quantitative evaluation, and \( P < 0.05 \) was considered significant.

Results

Frequency of lac peaks
The frequency of lac peaks relative to tumor grade is shown in Table 1. Lac peaks were significantly associated with Grade I (Fig. 1), Grade III, and Grade IV tumors. Remarkably, all Grade I tumors had lac peaks. Conversely, only one of 11 Grade II tumors had a lac peak. Statistically, the frequency of lac peaks was significantly different across tumor grades (\( P < 0.05 \)).

Frequency of lac/lip combined peaks
One lac/lip combined peak was observed among 12 lac peak positive Grade III tumors (Table 2). Among 18 lac peak positive Grade IV tumors, eight cases exhibited lac/lip combined peaks. One example is described in Fig. 2. Lac/lip combined peaks were significantly more frequent in Grade IV tumors compared to Grade III tumors (\( P = 0.04 \)).

Frequency of lip peaks
There were three clear lipid peak tumors and all were glioblastoma. One example is described in Fig. 3.

Quantitative evaluation of lac peaks
No significant differences were found between Grade I, III, or IV tumors.

| Grade | Cases | Frequency (%) |
|-------|-------|---------------|
| 1     | 3/3   | 100.0         |
| 2     | 1/11  | 9.1           |
| 3     | 12/15 | 80.0          |
| 4     | 18/26 | 69.2          |
Table 2. Lac/lip peak frequency among lactate-peak positive cases

| Grade | Cases | Frequency (%) |
|-------|-------|---------------|
| 1     | 0/3   | 0             |
| 2     | 0/1   | 0             |
| 3     | 1/12  | 8.3           |
| 4     | 8/18  | 44.4          |

Lac/lip, Lactate and lipid combined.

**Discussion**

Grading neuroepithelial tumors accurately have significant implications for the management of patients because low and high-grade tumors are treated differently. For low-grade tumors, resection is usually undertaken at the time of diagnosis. The potential benefits of this approach include more accurate diagnosis, rapid palliation of symptoms, extension of survival, reduced chance of malignant transformation, and cure.\(^\text{10}\) The utility of adjuvant therapy, such as chemotherapy or radiotherapy, is not well established.\(^\text{11,12}\)

On the other hand, the utility of radiotherapy and chemotherapy after surgery is well established for patients diagnosed with high-grade tumors,\(^\text{13,14}\) and if considered safe, surgery for maximal tumor resection extends survival when compared to biopsy, subtotal or partial resection.\(^\text{10}\)

Preoperative tumor grading is also important for accurate prognosis, which varies according to tumor grade. Five-year survival rates for Grades I, II, III, and IV brain tumors are 94%, 51.6%, 25.2%, and 8.9%, respectively.\(^\text{15,16}\)

From conventional MR imaging is sometimes unreliable. One study demonstrated contrast enhancement in 66.7%, 75.0%, and 100% of grade II, III, and IV gliomas, respectively, which suggests it is difficult to grade gliomas precisely based on structural imaging.\(^\text{17}\)

\(^1\)H-MRS is a noninvasive technique that is receiving increased attention for the diagnosis of brain tumors before surgery, and may assist with tumor grading.\(^\text{18}\) The technique provides additional information on metabolic activity in particular areas of the tumor, and can measure various metabolic indicators in vivo, such as Cho, Cr, NAA and pathologic levels of lac and lip. The non-invasive assessment of a combination of these parameters has been reported to increase the diagnostic accuracy of glioma grading.\(^\text{19}\)

There is extensive literature demonstrating the metabolic ratios of Cho/Cr, NAA/Cr, mlns/Cr to be useful in grading tumors and predicting malignancy. The sensitivities of Cho/Cr and Cho/NAA were 97.5% and 96.7%, respectively, in this study confirming that metabolite ratios can be useful for determining tumor grade. However, low specificities were noted due to the high levels of Cho that were observed in low-grade gliomas.\(^\text{20}\)

Although a lac peak is absent in healthy brain tissue, it is produced under conditions of anaerobic glycolysis commonly associated with pathological conditions such as hypoxia and hyperglycemia.\(^\text{6}\) High lac concentrations have been reported in both benign and malignant brain tumors, suggesting that the condition is independent of tumor grade.\(^\text{3}\)

Consistent with these data, we detected lac peaks in Grade I, III and IV brain tumors. However, we hypothesize that the etiology of benign and malignant brain tumors is different.
Fig. 2 Glioblastoma in a 69-year-old woman. (A) Axial \( T_1 \)-weighted images \((T_1\text{WI})\) shows an irregular low signal intensity mass mainly located in the left basal ganglia. (B) Axial \( T_2 \)-weighted images \((T_2\text{WI})\) shows a heterogeneous signal mass extending into the temporal lobe. Due to the mass effect, the left ventricle is obliterated. (C) Axial Gd \( T_1\text{WI} \) shows heterogeneous enhancement with a thick irregular wall. The mass consists of linear, nodular enhancement areas and a no enhancement area suggesting cyst or necrosis. (D) Magnetic resonance spectroscopy (MRS) shows lip peak (arrow) as well as a lac peak which is defined as “lac and lip (lac/lip) combined”.

Fig. 3 Glioblastoma in a 56-year old man. (A) Axial \( T_1 \)-weighted images \((T_1\text{WI})\) shows a low intensity mass in the lower temporal lobe. (B) Axial \( T_2 \)-weighted images \((T_2\text{WI})\) shows heterogeneous intensity that consists of intermediate signal intensity and high intensity at the central portion. (C) Axial Gd and coronal Gd. (D) \( T_1\text{WI} \) shows heterogeneous enhancement with a thick irregular wall. (E) Magnetic resonance spectroscopy (MRS) \((\text{TE} = 144 \text{ ms})\) shows a prominent lip peak (long arrow indicates the peak at 1.3 and short arrow indicates the peak at 0.9 ppm).
with Grade I tumors characterized by hypermetabolic glucose consumption, and Grade III and IV tumors producing lactate under hypoxic conditions and/or in association with an increased incidence of necrotic tissue.

Our results showed that among lac positive tumors that also exhibited lip peaks, a Grade IV classification was more likely, and a clear lipid peak was associated with glioblastoma (Grade IV tumors). Our data linking lip peaks with Grade IV tumors are consistent with earlier reports of high lip peaks in glioblastoma, which has been ascribed to an increased incidence of necrotic regions in these highly aggressive tumors.21

Our study is to classify the grading (from Grade I to Grade IV) of the neuroepithelial tumor. These include glioma and non-glioma (medulloblastoma and ependymoma). Medulloblastoma and ependymoma show no lactate nor lipid peak according to the previous study which was applied short and long TE.22 If we had focused on glioma, we would have different results. We would like to know the significance of the primary neuroepithelial tumor throughout Grade I to Grade IV.

When considering 1H-MRS as a diagnostic tool for neuroepithelial tumors, the presence of a lac peak may be useful to largely rule out the presence of Grade II tumors, and allow the subsequent differentiation of Grade I tumors from Grade III or IV tumors by conventional imaging. Grade IV tumors can then be diagnosed based on the presence of a lip peak. When we see the malignant tumor, we think as a rule lac is associated with grade III, while lipid is associate with grade IV. It is important that we can clearly demonstrate the significance of lac and lipid separately, although lac and lipid cannot be precisely differentiated using the medium echo time (TE = 144 ms) applied in this study.

1H-MRS may be very useful for monitoring benign glioma that present initially without a lac peak. The later appearance of a lac peak may signify malignant transformation (Grade II to Grade III), prompting more aggressive intervention.

There are a number of limitations to our study. Firstly, above mentioned, all the spectra were based on a medium echo time (TE = 144 ms), which is potentially problematic for the differentiation of lactate and lipid peaks, which have similar locations at 1.3 ppm. Only clear downward peaks were defined as lac peaks, and the presence of upward and downward peaks was defined as lac and lipid combinations. A more precise differentiation of lac and lipid contributions might be attained if several proton MRS examinations with different echo times (TE = 35, 288 ms) were used. However, such an approach would significantly increase the investigation time and be impractical in a clinical setting. It is possible that because we regarded only downward peaks as lac peaks, we have underestimated lac peak frequency as a result of some lac peaks being masked by positive lipid peaks.

Secondly, the retrospective nature of our study should also be considered as a limitation.

Finally, our study was not classified as histological type, but only as classified as grading. If the histologic type was uniformed, we would have different results.

Conclusions

Our data suggest that the presence of a lac peak is a clear predictor of a Grade I, II, or IV brain tumor, while diagnosis of a Grade II tumor is less likely. It is important to consider conventional imaging for the differentiation of Grade I from Grade III or IV tumors. The presence of lac/lipid combination peaks or clear lip peaks is most consistent with Grade IV tumors.

Conflicts of Interest

The authors does not have any conflicts of interest to declare.

References

1. McKnight TR. Proton magnetic resonance spectroscopic evaluation of brain tumor metabolism. Semin Oncol 2004; 31:605–617.
2. Tien RD, Lai PH, Smith JS, Lazeyras F. Single-voxel proton brain spectroscopy exam (PROBE/SV) in patients with primary brain tumors. Am J Roentgenol 1996; 167:201–209.
3. Fulham MJ, Bizzi A, Dietz MJ, et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 1992; 185:675–686.
4. Sijens PE, Levendag PC, Vecht CJ, van Dijk P, Oudkerk M. 1H MR spectroscopy detection of lipids and lactate in metastatic brain tumors. NMR Biomed 1996; 9:65–71.
5. Henriksen O, Wieslander S, Gjerris F, Jensen KM. In vivo 1H-spectroscopy of human intracranial tumors at 1.5 tesla. Preliminary experience at a clinical installation. Acta Radiol 1991; 32:95–99.
6. Yamasaki F, Kurisu K, Kajiwara Y, et al. Magnetic resonance spectroscopic detection of lactate and lactate in metastatic brain tumors. NMR Biomed 1991; 32:95–99.
7. Shimizu H, Kumabe T, Tominaga T, et al. Noninvasive evaluation of malignancy of brain tumors with proton MR spectroscopy. Am J Neuroradiol 1996; 17:737–747.
8. Sibtain NA, Howe FA, Saunders DE. The clinical value of proton magnetic resonance spectroscopy in adult brain tumours. Clin Radiol 2007; 62:109–119.
9. Louis DN, Ohagaki H, Wieslander OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica 2007; 114:97–109.
10. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008; 62:753–764.
11. Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg 1993; 78:909–914.
12. van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-
grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005; 366:985–990.

13. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359:1011–1018.

14. Stupp R, Mason WP, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987–996.

15. Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol 2013; 15 Suppl 2:ii1–ii56.

16. Jung KW, Yoo H, Kong HJ, Won YJ, Park S, Lee SH. Population-based survival data for brain tumors in Korea. J Neurooncol 2012; 109:301–307.

17. Roy B, Gupta RK, Maudsley AA, et al. Utility of multiparametric 3-T MRI for glioma characterization. Neuroradiology 2013; 55:603–613.

18. Porto L, Kieslich M, Franz K, Lehrbecher T, Pilatus U, Hattingen E. Proton magnetic resonance spectroscopic imaging in pediatric low-grade gliomas. Brain Tumor Pathol 2010; 27:65–70.

19. Fudaba H, Shimomura T, Abe T, et al. Comparison of multiple parameters obtained on 3T pulsed arterial spin-labeling, diffusion tensor imaging, and MRS and the Ki-67 labeling index in evaluating glioma grading. AJNR Am J Neuroradiol 2014; 35:2091–2098.

20. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003; 24:1989–1998.

21. Majós C, Alonso J, Aguilera C, et al. Proton magnetic resonance spectroscopy (1H MRS) of human brain tumours: assessment of differences between tumour types and its applicability in brain tumour categorization. Eur Radiol 2003; 13:582–591.

22. Schneider JF, Confort-Gouny S, Viola A, et al. Multiparametric differentiation of posterior fossa tumors in children using diffusion-weighted imaging and short echo-time 1H-MR spectroscopy. J Magn Reson Imaging 2007; 26:1390–1398.